Top Story

Aflibercept for AMD decreases exudation, does not improve VA

October 30, 2014

Eylea decreased exudation in a majority of patients with age-related macular degeneration previously treated with Avastin and/or Lucentis; however, visual acuity did not improve, according to study results.

The retrospective study included 67 eyes of 63 patients with exudative AMD who were treated with Eylea (aflibercept, Regeneron) for persistent exudation after having received at least three injections of Lucentis (ranibizumab, Genentech) or Avastin (bevacizumab, Genentech).

figure Lindstrom's PerspectivePublication Exclusive

Numbers help tell the story of glaucoma diagnosis, treatment

October 30, 2014
In general, if we can put a number on something, it is easier to understand and interpret. Advanced diagnostics along with older well-established techniques are…
figure Meeting News CoverageVideo

Light adjustable lens allows precise refractive results

October 30, 2014
CHICAGO – At the American Academy of Ophthalmology, James Lehmann, MD, discusses his clinical study results using the Calhoun Light Adjustable Lens in cataract…
In the Journals

AMD severity in first eye foretells incidence, progression in fellow eye

October 29, 2014
Severity of age-related macular degeneration in one eye was associated with an increased incidence of disease and progression in the fellow eye, according to study…
More News Headlines »
Cover Story Publication Exclusive
figure

Emerging technologies open new horizons in glaucoma structural evaluation, management

Ocular Surgery News U.S. Edition, October 25, 2014
Technological evolution, with optical coherence tomography in the forefront, is gradually but radically changing the…
More »
Blog

Soothe XP returns to the market

October 9, 2014
How about some plain old, good news? Soothe XP is back on the market for our patients with dry eye syndrome.This is…
More »
Meeting News Coverage Video
figure

Light adjustable lens allows precise refractive results

October 30, 2014
CHICAGO – At the American Academy of Ophthalmology, James Lehmann, MD, discusses his clinical study results…
More »